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Abstract
Background: Chemoresistance is the principal reason for poor survival and disease recurrence in osteosarcoma patients.
Inosine 59-monophosphate dehydrogenase type II (IMPDH2) encodes the rate-limiting enzyme in the de novo guanine
nucleotide biosynthesis and has been linked to cell growth, differentiation, and malignant transformation. In a previous
study we identified IMPDH2 as an independent prognostic factor and observed frequent IMPDH2 overexpression in
osteosarcoma patients with poor response to chemotherapy. The aim of this study was to provide evidence for direct
involvement of IMPDH2 in the development of chemoresistance.
Methodology/Principal Findings: Stable cell lines overexpressing IMPDH2 and IMPDH2 knock-down cells were generated
using the osteosarcoma cell line Saos-2 as parental cell line. Chemosensitivity, proliferation, and the expression of apoptosis-
related proteins were analyzed by flow cytometry, WST-1-assay, and western blot analysis. Overexpression of IMPDH2 in
Saos-2 cells induced strong chemoresistance against cisplatin and methotrexate. The observed chemoresistance was
mediated at least in part by increased expression of the anti-apoptotic proteins Bcl-2, Mcl-1, and XIAP, reduced activation of
caspase-9, and, consequently, reduced cleavage of the caspase substrate PARP. Pharmacological inhibition of IMPDH
induced a moderate reduction of cell viability and a strong decrease of cell proliferation, but no increase in
chemosensitivity. However, chemoresistant IMPDH2-overexpressing cells could be resensitized by RNA interference-
mediated downregulation of IMPDH2.
Conclusions: IMPDH2 is directly involved in the development of chemoresistance in osteosarcoma cells, suggesting that
targeting of IMPDH2 by RNAi or more effective pharmacological inhibitors in combination with chemotherapy might be a
promising means of overcoming chemoresistance in osteosarcomas with high IMPDH2 expression.
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Introduction
Osteosarcoma is the most common primary malignant tumor of
bone, typically affecting the long tubular bones of children and
adolescents. The prognosis of high-grade osteosarcoma treated
with surgery alone has been very poor, with 5-year survival rates
below 20% [1]. Major advances in treatment over the past three
decades, in particular the introduction of neoadjuvant chemo-
therapy, have markedly improved the outcome, with long-term
relapse-free survival rates ranging from 55% to 75% [2,3].
However, the remainder of patients respond poorly to chemo-
therapy with an increased risk of relapse and the development of
metastasis. Further efforts to improve patient outcome, for
example by means of novel treatment protocols, have not
significantly affected overall and disease-free survival of osteosar-
coma patients over the past 20 years [4,5]. The lack of
responsiveness to chemotherapy due to intrinsic or acquired
chemoresistance is the major reason for poor survival and disease
relapse of osteosarcoma patients. However, the mechanisms
underlying osteosarcoma chemoresistance remain largely un-
known. Therefore, the identification of prognostic factors that
allow risk stratification at the time of diagnosis and elucidation of
the mechanisms underlying chemoresistance will be pivotal in the
development of new therapeutic strategies. In a previous study we
identified IMPDH2 (inosine monophosphate dehydrogenase, type
II) as independent prognostic factor for the response to
chemotherapy in osteosarcoma patients. IMPDH2 gene expression
was significantly elevated in patients with poor response and
significantly associated with poor event-free survival [6].
IMPDH encodes the rate-limiting enzyme in de novo guanine
nucleotide biosynthesis, maintaining the cellular guanine deoxy-
nucleotide and ribonucleotide pools needed for DNA and RNA
synthesis. IMPDH has been linked to cell growth, differentiation,
and malignant transformation [7–10]. Two isoforms of IMPDH
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cells, whereas type II activity has been shown to be increased in
proliferating and especially malignant cells [10–11]. Thus,
IMPDH has been considered an attractive target for immunosup-
pression as well as antiviral and cancer therapy [12–15]. IMPDH
inhibitors such as tiazofurin and benzamide riboside have been
shown to induce terminal differentiation in a variety of human
cancer cells [16,17] and have been successfully applied in clinical
trials [18,19]. Furthermore, IMPDH2 has been shown to be
overexpressed in methotrexate (MTX)-resistant erythroleukemia
K562 and human colon cancer cells. Pharmacological inhibition
of IMPDH sensitized these cells to MTX treatment, suggesting
that IMPDH might be a target for the modulation of
chemosensitivity [20,21].
The aim of the present study was to investigate whether
IMPDH2 is directly involved in the development of chemoresis-
tance in osteosarcomas and whether inhibition of IMPDH2 activity
or gene expression might usefully improve the outcome of therapy.
Our results demonstrate that IMPDH2 overexpression induces a
strong chemoresistance in osteosarcoma cells which is mediated at
least in part by increased expression of anti-apoptotic proteins.
Although IMPDH2 knock-down or pharmacological inhibition of
IMPDH2 enzyme activity did not significantly influence the
chemosensitivity of wild-type osteosarcoma cells, chemoresistant
IMPDH2-overexpressing Saos-2 cells were resensitized by
IMPDH2 knock-down.
Results
The observation in our previous study of frequent IMPDH2
overexpression in osteosarcoma patients with poor response to
chemotherapyand the identificationofIMPDH2asanindependent
prognostic marker for chemotherapy response suggest that
IMPDH2 might be directly involved in the development of
chemoresistance. To verify this hypothesis we established osteosar-
coma cell lines with modulated IMPDH2 expression either by
overexpression of the IMPDH2 coding sequence in Saos-2 cells
(Saos-2 cdsIMPDH2) or by IMPDH2 knock-down using an shRNA
construct specific for IMPDH2 (Saos-2 shIMPDH2). Western blot
analysis of IMPDH2 protein expression in these cell lines showed a
marked increase of IMPDH2 expression in Saos-2 cdsIMPDH2
cells and a considerable knock-down of IMPDH2 protein
expression in Saos-2 shIMPDH2 cells compared to wild-type cells
and cells stably transfected with the empty vector (Fig. 1A).
The analysis of chemosensitivity revealed a strong resistance of
IMPDH2-overexpressing Saos-2 cdsIMPDH2 cells against cisplat-
in and methotrexate (Fig. 1B+C). Concerning the calculated IC50
values, overexpression of IMPDH2 induced 118-fold resistance
against cisplatin and 14-fold resistance against methotrexate
compared to Saos-2 wild-type cells (Table 1). Contrary to our
expectations, IMPDH2 knock-down did not enhance the chemo-
sensitivity of Saos-2 cells (Fig. 1B+C). At high MTX concentra-
tions Saos-2 shIMPDH2 cells even showed a slightly more resistant
phenotype rather than the expected sensitive phenotype. We
assume that the reduced proliferation rate of IMPDH2 knock-
down cells influences the susceptibility of these cells to cytotoxic
drugs and that this effect is more pronounced for MTX, which
acts much more slowly than cisplatin.
As chemotherapeutic drugs are known to exert their effects
mainly through the activation of the mitochondrial apoptosis
pathway, we further analyzed the expression of several key players
in this pathway in cisplatin-treated Saos-2 wild-type and Saos-2
cdsIMPDH2 cells by western blotting. Cleavage of poly-ADP-
ribose polymerase (PARP), a downstream substrate of caspase-9,
was markedly reduced in IMPDH2-overexpessing cells. Further-
more, the cleavage and therefore the activation of caspase-9 was
strongly reduced in these cells (Fig. 2). In addition, untreated Saos-
2 cdsIMPDH2 cells showed increased expression of the anti-
apoptotic mitochondrial proteins Bcl-2 and Mcl-1 compared to
Saos-2 wild-type cells. Upon cisplatin treatment Bcl-2 expression
was upregulated in Saos-2 wild-type cells while it was downreg-
ulated in IMPDH2-overexpressing cells. Mcl-1 expression was
Figure 1. Chemoresistance in IMPDH2-overexpressing Saos-2
cells. A: Western blot analysis of IMPDH2 expression in Saos-2 wild-
type cells, Saos-2 cells transfected with the empty vector (Saos-2 pCMS),
Saos-2 cells overexpressing IMPDH2 (Saos-2 cdsIMPDH2), and Saos-2
cells transfected with a shRNA construct directed against IMPDH2 (Saos-
2 shIMPDH2). B: Cell viability of different Saos-2 cell lines after
treatment with cisplatin at the indicated concentrations for 72 h.
Analyses were performed in triplicate and the results are presented as
mean 6 SD (** p,0.01 compared to Saos-2 wild-type cells). C: Cell
viability of different Saos-2 cell lines after treatment with methotrexate
(MTX) at the indicated concentrations for 96 h. Analyses were
performed in triplicate and the results are presented as mean 6 SD
(** p,0.01 compared to Saos-2 wild-type cells).
doi:10.1371/journal.pone.0012179.g001
IMPDH2 Induced Chemoresistance
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dropped below control levels after 48 h of treatment. In contrast,
Mcl-1 expression in Saos-2 cdsIMPDH2 cells remained un-
changed at a high level over the whole observation period (Fig. 2).
The expression of the x-linked inhibitor of apoptosis protein
(XIAP), a member of the inhibitor of apoptosis family of proteins
(IAP), was identical in the untreated cell lines. However, cisplatin
decreased the expression of XIAP in wild-type cells while it
induced increased expression of XIAP in IMPDH2-overexpressing
cells (Fig. 2). These findings indicate that the observed chemore-
sistance of IMPDH2-overexpressing osteosarcoma cells may be due
at least in part to increased expression of anti-apoptotic proteins,
reduced activation of caspase-9, and, as a consequence, decreased
cleavage of PARP.
The effects of inhibition of IMPDH2 enzyme activity on cell
viability and chemosensitivity were evaluated using mycophenolic
acid (MPA), an IMPDH inhibitor with a five times higher affinity
to IMPDH2 than to the isoform IMPDH1. MPA alone induced
concentration-dependent cell death in Saos-2 wild-type, Saos-2
pCMS, and Saos-2 shIMPDH2 cells. In Saos-2 cdsIMPDH2 cells
only the highest MPA concentration induced a slight decrease in
cell viability. However, MPA did not influence the chemosensi-
tivity of any of the tested cell lines to cisplatin (Fig. 3). As the
susceptibility of cells to treatment with chemotherapeutic drugs is
highly dependent on cell growth, we analyzed the effects of MPA
on cellular proliferation. MPA inhibited cell proliferation in a
concentration-dependent manner in all tested Saos-2 cell lines
(Fig. 4A).
To verify that the observed antiproliferative effect of MPA was
due to a depletion of guanine nucleotides caused by the inhibition
of IMPDH, Saos-2 wild-type cells were treated with MPA with or
without the addition of guanine. Guanine almost completely
abolished the antiproliferative effects of MPA, indicating a specific
inhibition of IMPDH enzyme activity (Fig. 4B).
Since the pharmacological inhibition of IMPDH2 did not
influence the chemoresistance of IMPDH2-overexpressing
Saos-2 cells, we analyzed whether reduction of IMPDH2 gene
expression is sufficient to provoke resensitization of these cells.
For this purpose we cotransfected Saos-2 cdsIMPDH2 cells
with three different shRNA constructs specific for IMPDH2
and generated stable cell lines. IMPDH2 mRNA levels were
52–60% lower in these cell lines than in the parent Saos-2
cdsIMPDH2 cells (Fig. 5A). Upon treatment with cisplatin,
cotransfection of shIMPDH2 significantly decreased the
amount of viable cells compared to Saos-2 cdsIMPDH2 cells.
At high cisplatin concentrations the chemosensitivity of these
cells was comparable to that of Saos-2 pCMS control cells
(Fig. 5B).
Discussion
The existence or development of intrinsic or acquired
chemoresistance represents the principal reason for poor survival
and disease recurrence in osteosarcoma patients. Unfortunately,
the mechanisms underlying osteosarcoma chemoresistance remain
largely unknown. However, knowledge of the mediators that
contribute to chemoresistance is pivotal to the identification of
high-risk patients and the development of new therapeutic
strategies. In order to identify prognostic factors for chemotherapy
response we previously screened osteosarcoma cell lines for drug-
regulated genes. Among other genes, we observed upregulation of
IMPDH2 in response to cytotoxic drugs [22]. We further screened
osteosarcoma biopsies for IMPDH2 gene expression and correlated
these data with the patients’ response to chemotherapy as well as
their overall and event-free survival. Expression of IMPDH2 was
frequently increased in the subgroup of patients with poor
response to chemotherapy and turned out to be an independent
prognostic factor significantly associated with chemotherapy
response and event-free survival [6]. These data suggested that
IMPDH2 might be directly involved in the development of
chemoresistance. In fact, the findings of the present study
demonstrate that overexpression of IMPDH2 in osteosarcoma
cells induces strong chemoresistance to cisplatin and methotrexate,
two drugs frequently used for osteosarcoma therapy. As chemo-
therapeutic drugs exert their cytotoxic effects mainly through the
activation of the mitochondrial apoptosis pathway, we investigated
the expression of several apoptosis-related factors. Untreated
IMPDH2-overexpressing Saos-2 cells displayed increased expres-
Table 1. IC50 values of cisplatin and methotrexate in different
Saos-2 cell lines.
Cisplatin Methotrexate
(72 h, mg/ml) (96 h, ng/ml)
Saos-2 wild-type 2.4960.11 17.7261.7
Saos-2 pCMS 2.1160.70 16.9761.1
Saos-2 cdsIMPDH2 295626 245655
Saos-2 shIMPDH2 2.6160.75 32.13612
values are presented as mean 6 SEM.
doi:10.1371/journal.pone.0012179.t001
Figure 2. Western blot analysis of different apoptosis-related
proteins in Saos-2 wild-type cells and Saos-2 cdsIMPDH2 cells
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upregulation of XIAP upon cisplatin treatment. As a consequence,
activation of caspase-9 and cleavage of the caspase substrate PARP
were markedly reduced in these cells upon treatment with
cisplatin, demonstrating IMPDH2-mediated inhibition of the
mitochondrial apoptosis pathway. Interestingly, the IMPDH
inhibitor mycophenolate mofetil (MMF) has been shown to induce
caspase-dependent apoptosis in myeloma cells. Moreover, the pro-
apoptotic mitochondrial proteins Bak and Bax have been shown to
play an important role in the regulation of apoptotic cell death
which is strongly associated with the depletion of the intracellular
GTP pool [23]. Thus, the IMPDH-dependent regulation of
intracellular GTP-pools seems to be crucial for the balance of anti-
and pro-apoptotic proteins, which for their part influence the
susceptibility of the cell to apoptotic stimuli, including cytotoxic
drugs.
As catalyst of the rate-limiting step in the de novo synthesis of
guanine nucleotides, IMPDH2 has been identified as an important
regulator of cell proliferation [9]. In particular, proliferating
lymphocytes are strongly dependent on the de novo synthesis of
nucleotides, making IMPDH an attractive target for immunosup-
pressive therapies. IMPDH inhibitors such as MMF and its active
compound MPA are thus widely used as immunosuppressive
agents. Likewise, rapidly proliferating neoplastic cells are charac-
terized by a high demand on IMPDH-mediated nucleotide
synthesis. Expression of IMPDH, particularly the type II isoform,
has been shown to be significantly increased in many types of
malignancies, making IMPDH2 also an attractive target for cancer
therapy [10–12,24,25]. Several studies have already demonstrated
the cytotoxic effects of IMPDH inhibitors and their high potential
as anticancer drugs [26–28]. Phase II/III trials of IMPDH
inhibitors such as tiazofurin and benzamide riboside have been
conducted with very promising results, although studies were
terminated due to neurotoxic side effects [18,19,29]. Although the
essential role of IMPDH in cancer cell proliferation has been
extensively studied, little is known about the involvement of this
enzyme in the regulation of chemosensitivity. Increased IMPDH
mRNA levels have been detected in MTX-treated and MTX-
resistant human colon cancer and erythroleukemia cells. Inhibition
of IMPDH significantly increased the sensitivity of the resistant cell
lines to MTX, indicating that targeting IMPDH might constitute a
promising means of minimizing the development of resistance
[20,21]. We did not detect an increase in chemosensitivity in
osteosarcoma cells treated with the IMPDH inhibitor MPA.
Likewise, knock-down of IMPDH2 gene expression did not
sensitize Saos-2 wild-type cells to cisplatin or methotrexate.
Because of these unexpected observations and the fact that
cytotoxic drugs preferentially act on rapidly proliferating cells, we
assumed that the antiproliferative actions of IMPDH2 inhibitors
counteract their effects on chemosensitivity. In fact, MPA induced
a strong dose-dependent decrease in cell proliferation with an
expected higher sensitivity of IMPDH2 knock-down cells and a
lower sensitivity of IMPDH2-overexpressing cells. Besides cell
proliferation, the p53 status of the analyzed Saos-2 cells might
contribute to the failure of MPA to induce chemosensitivity. Saos-
2 cells have a p53 null genotype and were chosen because p53
mutations and p53 inactivation are common features of osteosar-
comas. The p53 gene functions as a key regulator of the apoptotic
program. It is activated in response to cellular stress and exerts its
well-documented pro-apoptotic functions mainly in a transcrip-
tion-dependent manner. The IMPDH inhibitor MPA has been
shown to activate and stabilize p53, which in turn mediates cell
cycle arrest and apoptosis in response to guanine nucleotide
depletion [30–32]. These data suggest that a functional p53
pathway is required for the induction of apoptosis in response to
nucleotide depletion caused by IMPDH inhibitors. While
Figure 3. Chemosensitivity of Saos-2 wild-type, Saos-2 pCMS, Saos-2 shIMPDH2, and Saos-2 cdsIMPDH2 cells treated with the
IMPDH inhibitor mycophenolic acid (MPA) at the indicated concentrations for 72 h with or without cisplatin (2.5 mg/ml). Analyses
were performed in triplicate and the results are presented as mean 6 SD.
doi:10.1371/journal.pone.0012179.g003
IMPDH2 Induced Chemoresistance
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cantly alter the chemosensitivity of the analyzed cells, IMPDH2-
overexpressing cells could be resensitized by cotransfection of an
IMPDH2-specific shRNA construct. In association with the
observed decrease in IMPDH2 gene expression, sensitivity to
cisplatin increased, reaching the sensitivity levels of control cells at
high cisplatin concentrations.
Altogether, we were able to demonstrate the induction of strong
chemoresistance in osteosarcoma cells by overexpression of
IMPDH2. The observed chemoresistance is mediated at least in
part by upregulation of anti-apoptotic proteins, leading to
inhibition of the mitochondrial apoptotic signaling pathway.
Pharmacological inhibition of IMPDH2 did not enhance chemo-
sensitivity, probably due to the strong antiproliferative effects of
the inhibitor or the absence of functional p53. However, reduction
of IMPDH2 gene expression in IMPDH2-overexpressing cells
resensitized these cells to cytotoxic drugs. As IMPDH2 overex-
pression is frequently observed in osteosarcoma patients with poor
Figure 4. Influence of the IMPDH inhibitor mycophenolic acid (MPA) on cell proliferation of different Saos-2 cell lines. A: MPA was
added to the culture medium at the indicated concentrations and cell proliferation was determined using WST-1 assay at 0, 24, 48, and 72 h. B: Saos-
2 wild-type cells were treated with the indicated concentrations of MPA for 48 h with or without the addition of 10 mM guanine. Cell proliferation was
analyzed by WST-1 assay at 450 nm. Analyses were performed in triplicate and the results are presented as mean 6 SD.
doi:10.1371/journal.pone.0012179.g004
IMPDH2 Induced Chemoresistance
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more effective inhibitors in combination with chemotherapy might
provide an effective synergistic treatment to overcome chemore-
sistance in osteosarcomas. It is clear that this hypothesis is still at a
very early stage of development but add an interesting point of
discussion and explanation of the observed effects.
Materials and Methods
Cell culture and drug treatment
The human osteogenic sarcoma cell line Saos-2 was originally
obtained from the American Type Culture Collection (Rock-
ville, USA). Cells were maintained in RPMI 1640 (Lonza
GmbH, Wuppertal, Germany) containing 2 mM L-glutamine
and 25 mM HEPES and supplemented with fetal calf serum
(Biochrom, Berlin, Germany), and 100 U/ml penicillin/strep-
tomycin (Lonza GmbH) at 37uCi nah u m i d i f i e d5 %C O 2
atmosphere. Cells were kept in a logarithmic growth phase and
split following treatment with trypsin/EDTA (Lonza GmbH),
washed in PBS, and replated in fresh culture medium. For drug
treatment, cisplatin (Sigma-Aldrich, Taufkirchen, Germany)
was dissolved in N,N-dimethylformamide at a concentration of
15 mg/ml and added to the culture medium in the indicated
concentrations. Methotrexate was dissolved in 0.01N NaOH
and further diluted in PBS to a concentration of 10 mg/ml.
Mycophenolic acid (Sigma-Aldrich) was dissolved in methanol
at a concentration of 50 mM and added to the culture medium
in the indicated concentrations.
Transfection and generation of stable cell lines
For overexpression of IMPDH2 the full coding sequence of
IMPDH2 was cloned into the mammalian expression vector
pCMS-EGFP (Clontech, Germany) and verified by sequencing.
For gene knock-down a commercially available shRNA expression
Figure 5. Chemosensitivity of Saos-2 cdsIMPDH2 cells cotransfected with an IMPDH2-specific shRNA construct. A: Stable Saos-2
cdsIMPDH2 cells were cotransfected with three different shRNA constructs directed against IMPDH2. Stable cell lines were generated, and IMPDH2
mRNA expression was analyzed by quantitative PCR and compared to that in Saos-2 wild-type, Saos-2 pCMS, and Saos-2 cdsIMPDH2 cells. B: Western
blot analysis of IMPDH2 expression in Saos2 cdsIMPDH2 cells cotransfected with an IMPDH2 specific shRNA construct. C: Analysis of chemosensitivity
of Saos-2 wild-type, Saos-2 pCMS, Saos-2 cdsIMPDH2, and Saos-2 cdsIMPDH2 cells stable cotransfected with shRNA construct specific for IMPDH2.
Cells were treated with cisplatin at the indicated concentrations for 72 h before cell viability was analyzed by propidiumiodide staining. Analyses
were performed in triplicate and the results are presented as mean 6 SD. (** p,0.01).
doi:10.1371/journal.pone.0012179.g005
IMPDH2 Induced Chemoresistance
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was used: 59-ATAGCCTCCATTCGTATGAGAAGCGGCTT-
39 (Origene, Rockville, USA). In both cases Saos-2 cells were
transfected by electroporation using 10
5 cells and 0.5 mg plasmid
and the microporator MP-100 (PeqLab, Erlangen, Germany).
Forty-eight hours after transfection, medium was replaced by fresh
medium containing 600 mg/ml geniticin (Sigma-Aldrich) for cells
transfected with the pCMS-EGFP vector or 1 mg/ml puromycin
(Sigma-Aldrich) for cells transfected with shRNA constructs.
Stable clones were selected for at least 4 weeks before single
colonies were picked and analyzed for IMPDH2 expression by
quantitative PCR and western blot.
Western blot analysis
Cells were washed in PBS, lyzed in RIPA buffer (Santa Cruz,
Heidelberg, Germany) containing protease inhibitor cocktail
(Santa Cruz), incubated for 1 h at 4uC, and centrifuged at
12000 g for 10 min. to remove cellular debris. Total protein
concentrations were determined by BCA-assay (Pierce, Rockford,
USA), and 10 mg of total protein was subjected to gel
electrophoresis. Proteins were separated on a 10% polyacrylamide
gel and transferred to Immobilon-P membranes (Millipore,
Schwalbach, Germany). After blocking in PBS supplemented with
5% skim milk (Sigma-Aldrich) and 0.05% Tween 20 (Sigma-
Aldrich) membranes were incubated overnight at 4uC with one of
the following primary antibodies at the indicated dilutions:
IMPDH2 (1:500) (Atlas Antibodies, Stockholm, Sweden), PARP
p85 (1:1000) (Promega, Mannheim, Germany), caspase-9 (1:1000)
(Cell Signaling Technology, Danvers, USA), bcl-2 (1:250)
(Calbiochem, San Diego, USA), mcl-1 (1:250) (Santa Cruz), XIAP
(1:1000) (Cell Signaling Technology), and actin (1:5000) (BD
Transduction Laboratories, Heidelberg, Germany). After incuba-
tion with the primary antibody, membranes were washed three
times with PBS containing 0.1% Tween 20 and incubated for 1 h
at room temperature with 5000-fold diluted peroxidase conjugated
goat anti-rabbit IgG (Santa Cruz) or goat anti-mouse IgG. Proteins
recognized by the antibody were visualized with LumiLight
western blotting substrate (Roche Diagnostics, Mannheim,
Germany) according to the manufacturer’s instructions.
Quantitative PCR
Two micrograms of total RNA extracted with RNeasy Mini kit
(Qiagen, Hilden, Germany) were reverse transcribed using Sensi-
script (Qiagen) and 10 mM oligo-dT primer for 2 h at 37uCi na
total volume of 20 ml. Quantitative real-time PCR was performed
in a LightCycler instrument (Roche Diagnostics) in a total volume
of 20 ml using the Absolute SYBR Capillary mix (Thermo
Scientific, Dreieich, Germany) and 1 ml of cDNA as template.
Samples were heated to 95uC for 15 min followed by 40 cycles of
denaturation at 95uC for 5 s, annealing at 58uC for 15 s, and
extension at 72uC for 20 s. After the last cycle, a melting curve
analysis was performed to verify the specificity of the amplified
PCR products. The amount of PCR product was calculated using
an external standard curve and LightCycler software. Calculated
gene expressions were normalized on the basis of the ß-actin
(ACTB) expression in the corresponding samples.
Analysis of chemosensitivity and cell proliferation
Cell viability was quantified by propidium iodide staining and
subsequent flow-cytometric analysis. For drug treatment 7.5610
4
cells were seeded in a 24-well plate 24 h before treatment. After
incubation for the indicated time, adherent and detached cells
were collected, washed in PBS, centrifuged, and resuspended in
PBS supplemented with 1% FCS and 2.5 mg/ml propidium iodide
(Invitrogen, Karlsruhe, Germany). Samples were directly analyzed
on a FACScalibur cytofluorimeter using the CellQuest software
(Becton Dickinson, Hamburg, Germany).
For the analysis of cell proliferation 2.5610
3 cells were seeded in
a 96-well plate. After 0, 24, 48, and 72 h, medium was replaced
with fresh medium containing 1/10 volume of cell proliferation
reagent WST-1 (Roche Diagnostics) and incubated for 2 h at
37uC before the absorbance at 450 nm was quantified in a
spectrophotometer.
Statistics
Statistical analysis was done using the two-tailed Student’s t-test
with p=0.01 considered the upper limit of statistical significance.
Data are presented as mean 6 SD.
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